Antibiotic. Antifungal and anti-yeast activity. Inhibits platelet aggregation induced by collagen or ADP. Has no effect on thrombin-induced platelet aggregation. Potent, cell permeable, reversible, ATP-competitive and broad spectrum inhibitor of protein kinases. Inhibits protein kinase A, CaM kinase, myosin light chain kinase, protein kinase C, protein kinase G, CDK1/cyclin B, CDK2/cyclin A, CDK4/cyclin D, CDK5/p25, GSK-3beta and Pim-1 kinase. Key apoptosis inducer. Topoisomerase II (Topo II) inhibitor.
Storage and Stability:
Short-term Storage: +4°C
Long-term Storage: +4°C
Stable for at least 2 years after receipt when stored at +4°C.
Purity: >99% (HPLC)
Important Note: This product as supplied is intended for research use only, not for use in human, therapeutic or diagnostic applications without the expressed written authorization of United States Biological.
Product Reference: |
A new alkaloid AM-2282 of Streptomyces origin. Taxonomy, fermentation, isolation and preliminary characterization: S. Omura, et al.; J. Antibiot. (Tokyo) 30, 275 (1977)
Staurosporine, a potent platelet aggregation inhibitor from a Streptomyces species: S. Oka, et al.; Agric. Biol. Chem. 50, 2723 (1986)
Staurosporine, a potent inhibitor of phospholipid/Ca++dependent protein kinase: T. Tamaoki, et al.; BBRC 135, 397 (1986)
Staurosporine inhibits tyrosine-specific protein kinase activity of Rous sarcoma virus transforming protein p60: N. Nakano, et al.; J. Antibiot. (Tokyo) 40, 706 (1987)
Staurosporine, K-252 and UCN-01: potent but nonspecific inhibitors of protein kinases: U.T. Ruegg & G.M. Burgess; TIPS 10, 218 (1989) (Review)
Staurosporine: an effective inhibitor for Ca2+/calmodulin-dependent protein kinase II: N. Yanagihara, et al.; J. Neurochem. 56, 294 (1991)
Induction of a common pathway of apoptosis by staurosporine: R. Bertrand, et al.; Exp. Cell Res. 211, 314 (1994)
Staurosporine induces programmed cell death in embryonic neurons and activation of the ceramide pathway: D.A. Wiesner & G. Dawson; J. Neurochem. 66, 1418 (1996)
Mechanism of topoisomerase II inhibition by staurosporine and other protein kinase inhibitors: P. Lassota et al.; J. Biol. Chem. 271, 26418 (1996)
Characterization of the cell death process induced by staurosporine in human neuroblastoma cell lines: J. Boix, et al.; Neuropharmacology 36, 811 (1997)
Molecular mechanism of staurosporine-induced apoptosis in osteoblasts: H.J. Chae, et al.; Pharmacol. Res. 42, 373 (2000)
Pim-1 ligand-bound structures reveal the mechanism of serine/threonine kinase inhibition by LY294002: M.D. Jacobs, et al.; J. Biol. Chem. 280, 13728 (2005)
|Intended for research use only. Not for use in human, therapeutic, or diagnostic applications.|